Autism-spectrum quotient
Autism-Spectrum Quotient (AQ) is a self-report questionnaire that was developed by the Autism Research Centre at the University of Cambridge. It is designed to measure the degree to which an adult with normal intelligence has traits associated with the autism spectrum.
Overview[edit]
The Autism-Spectrum Quotient consists of 50 questions, each of which is scored 1 point if the respondent's answer indicates autistic traits. The AQ is not a diagnostic tool, but a measure of traits associated with autism-spectrum conditions. It was first published by Simon Baron-Cohen, Sally Wheelwright, Richard Skinner, Joanne Martin, and E. Clubley in 2001.
Scoring and interpretation[edit]
The Autism-Spectrum Quotient has a maximum score of 50. In the initial study, individuals with Asperger syndrome or high-functioning autism scored an average of 35, compared to a control group average of 16. Scores of 32 or more are often used as a cut-off for indicating "clinically significant" levels of autistic traits.
Reliability and validity[edit]
The Autism-Spectrum Quotient has been found to have good reliability and validity in a number of studies. It has been translated into many languages and used in research worldwide.
Criticism and controversy[edit]
While the Autism-Spectrum Quotient is widely used in research, it has been criticized for its reliance on self-report, which can be influenced by a number of factors. Some researchers have also questioned the validity of using a single cut-off score to indicate clinically significant levels of autistic traits.
See also[edit]
- Autism Diagnostic Observation Schedule
- Autism Diagnostic Interview-Revised
- Diagnostic classification and rating scales used in psychiatry
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian